Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.65USD
17 Nov 2017
Change (% chg)

$-0.25 (-1.94%)
Prev Close
$12.90
Open
$12.90
Day's High
$12.90
Day's Low
$12.55
Volume
63,177
Avg. Vol
143,114
52-wk High
$20.40
52-wk Low
$9.35

Latest Key Developments (Source: Significant Developments)

Epizyme says ‍no revenue recognized in Q3 of 2017 compared to $6.6 mln for Q3 of 2016​
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Epizyme Inc :Epizyme reports third quarter 2017 operating results and company updates.Epizyme Inc - ‍no revenue recognized in q3 of 2017, compared to $6.6 million for q3 of 2016​.Epizyme Inc - ‍research and development (research and development) expenses were $28.7 million for q3 of 2017, compared to $23.9 million​.Epizyme Inc - ‍existing cash, cash equivalents and marketable securities as of sept 30 will be sufficient to fund planned operations into at least q3 2019​.  Full Article

Epizyme announces pricing of public offering of common stock
Thursday, 14 Sep 2017 06:30am EDT 

Sept 14 (Reuters) - Epizyme Inc ::Epizyme announces pricing of public offering of common stock.Says public offering of 9.18 million common shares priced at $15.25per share.  Full Article

Epizyme announces proposed public offering of common stock
Wednesday, 13 Sep 2017 04:01pm EDT 

Sept 13 (Reuters) - Epizyme Inc :Epizyme announces proposed public offering of common stock.Epizyme Inc says ‍intends to offer and sell $120 million of shares of its common stock in an underwritten public offering​.Epizyme-Will use ‍net proceeds from this offering,existing cash, cash equivalents,marketable securities,to fund development costs of tazemetostat outside Japan​.  Full Article

Epizyme says CFO ‍Andrew E. Singer will be leaving co at end of August​
Tuesday, 15 Aug 2017 06:30am EDT 

Aug 15 (Reuters) - Epizyme Inc :Epizyme announces leadership transition for finance organization.‍Andrew E. Singer, chief financial officer of Epizyme, will be leaving company at end of august​.Epizyme Inc - as part of transition, Susan Graf, chief business officer of Epizyme, will assume responsibility for finance organization going forward,.  Full Article

Epizyme reports Q2 loss of $0.48/shr
Friday, 4 Aug 2017 06:30am EDT 

Aug 4 (Reuters) - Epizyme Inc :Epizyme reports second quarter 2017 financial results and clinical and business progress.Epizyme Inc qtrly loss per share $0.48.Q2 revenue $10 million.Q2 revenue view $2.8 million -- Thomson Reuters I/B/E/S.  Full Article

Epizyme expands clinical collaboration with Genentech
Monday, 26 Jun 2017 06:30am EDT 

June 26 (Reuters) - Epizyme Inc :Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc.Epizyme inc - expanded its clinical collaboration with genentech, a member of roche group.Epizyme inc - under new agreement, tazemetostat administered in combination with atezolizumab will be evaluated in a phase 1b/2 clinical study.Epizyme inc - financial terms are not disclosed and epizyme will retain global development and commercialization rights to tazemetostat..Epizyme inc - genentech will sponsor planned phase 1b/2 clinical trial, which is expected to be initiated by end of 2017.  Full Article

Epizyme reports positive interim data from Phase 2 trial for tazemetostat
Wednesday, 14 Jun 2017 08:30am EDT 

June 14 (Reuters) - Epizyme Inc :Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients.Epizyme - interim data as of June 1, 2017 show that tazemetostat treatment resulted in a clinically meaningful benefit in patients with fl.Tazemetostat continues to demonstrate a favorable safety profile across all patient populations in this study.As size of mutation study groups increase and patients remain on study, epizyme expects data will continue to evolve.  Full Article

Epizyme says tazemetostat shows clinically meaningful activity
Thursday, 18 May 2017 06:00am EDT 

May 18 (Reuters) - Epizyme Inc ::Epizyme announces path toward Tazemetostat registration in Epithelioid sarcoma and reports new clinical data to be presented at ASCO.Says Tazemetostat demonstrates clinically meaningful activity in Epithelioid sarcoma.Says based on discussions with fda, company has identified a path to submission for accelerated approval of Tazemetostat.Says will target a new drug application (NDA) submission in 2018.  Full Article

Epizyme says no revenue was recognized in Q1 of 2017, compared to $0.5 mln for Q1 2016
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Epizyme Inc :Epizyme reports first quarter 2017 results and provides corporate update.Epizyme inc - no revenue was recognized in q1 of 2017, compared to $0.5 million for q1 of 2016.Epizyme - its cash, cash equivalents, marketable securities will be sufficient to fund co's planned operations into at least q3 of 2018.Epizyme inc qtrly loss per share $0.56.Q1 earnings per share view $-0.63, revenue view $352860.00 -- Thomson Reuters I/B/E/S.  Full Article

Epizyme quarterly loss per share $0.56
Monday, 8 May 2017 06:21am EDT 

May 8 (Reuters) - Epizyme Inc : :Quarterly loss per share $0.56 .  Full Article